BlueBrainBoost
freedom-pharmacy
Purchases through the above links give commission which helps fund this website
Recent literature: Phosphodiesterase-4 inhibitor
Date Journal Article title
2020 Jan J Drugs Dermatol Topical Agents for the Treatment of Atopic Dermatitis
2020 Jan Br J Pharmacol Roflupram exerts neuroprotection via activation of CREBPGC-1α signaling in experimental models of Parkinson's disease.
2020 Jan Drugs Apremilast: A Review in Oral Ulcers of Behçet's Disease.
2020 Jan Sci Rep Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock.
2020 Jan Clin Gastroenterol Hepatol Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
2019 Dec Int J Pharm Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals.
2019 Front Pharmacol CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice.
2019 Nov Int J Pharm Ex vivo (human skin) and in vivo (minipig) permeation of propylene glycol applied as topical crisaborole ointment, 2.
2019 Dec Mod Rheumatol Positioning of apremilast in treatment of Behçet's disease.
2019 Int J Trichology Apremilast in Refractory Alopecia Areata.
2019 Nov N Engl J Med Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
2020 Exp Parasitol The phosphodiesterase-4 inhibitor roflumilast impacts Schistosoma mansoni ovipositing in vitro but displays only modest antischistosomal activity in vivo.
2019 Oct Cell Mol Neurobiol Inhibition of PDE4 Attenuates TNF-α-Triggered Cell Death Through Suppressing NF-κB and JNK Activation in HT-22 Neuronal Cells.
2020 J Dermatol Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
2012 LiverTox: Clinical and Re... Roflumilast
2012 LiverTox: Clinical and Re... Apremilast
2020 Redox Biol Inhibition of PDE4 protects neurons against oxygen-glucose deprivation-induced endoplasmic reticulum stress through activation of the Nrf-2HO-1 pathway.
2019 Aug Eur J Dermatol Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata.
2020 Ann Allergy Asthma Immunol New treatments for atopic dermatitis targeting beyond IL-4IL-13 cytokines.
2019 Pharmacol Res Biological and synthetic target DMARDs in psoriatic arthritis.
2019 J Aerosol Med Pulm Drug D... Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent.
2019 Drug Discov Today Soft drugs for dermatological applications: recent trends.
2019 Expert Opin Investig Drugs Ensifentrine (RPL554): an investigational PDE34 inhibitor for the treatment of COPD.
2019 J Allergy Clin Immunol Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
2020 J Am Acad Dermatol Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
2019 Aug Respir Res Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.
2019 Jul Cell Death Dis Shifting the balance of autophagy and proteasome activation reduces proteotoxic cell death: a novel therapeutic approach for restoring photoreceptor homeostasis.
2019 Immunol Med Novel topical and systemic therapies in atopic dermatitis.
2019 Brain Behav Fear renewal activates cyclic adenosine monophosphate signaling in the dentate gyrus.
2020 J Am Acad Dermatol Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial.
2019 Am J Clin Dermatol Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
2019 Jun Br J Dermatol Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases.
2019 Diabetes Metab Syndr Obes Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweightobesity involve age-associated fat mass loss - results of an exploratory study.
2019 Dec Rheumatology (Oxford) Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
2019 Therap Adv Gastroenterol New biologics and small molecules in inflammatory bowel disease: an update.
2019 Biologics Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau.
2019 J Dermatol Drug survival of apremilast in a real-world setting.
2018 Best Pract Res Clin Rheum... Emerging treatment options for spondyloarthritis.
2019 Environ Toxicol Pivotal role of cAMP-PKA-CREB signaling pathway in manganese-induced neurotoxicity in PC12 cells.
2019 Indian J Dermatol Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic.
2019 J Eur Acad Dermatol Venereol Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.
2019 J Clin Aesthet Dermatol Recommendations for Initiating Systemic Therapy in Patients with Psoriasis.
2019 Jun J Med Chem Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
2019 Hepatology Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench.
2019 J Comp Eff Res Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
2019 CPT Pharmacometrics Syst ... Concentration-QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase-4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation.
2019 Mol Pharmacol Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis.
2019 Jul Neuropharmacology The antidepressant- and anxiolytic-like effects of resveratrol: Involvement of phosphodiesterase-4D inhibition.
2019 Dermatol Ther Nails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast.
2019 J Dermatol Sci Cytochemokine profile of in vitro scratched keratinocyte model: Implications of significant upregulation of CCL20, CXCL8 and IL36G in Koebner phenomenon.
2019 J Surg Res Phosphodiesterase-4 Inhibitor Roflumilast Attenuates Pulmonary Air Emboli-Induced Lung Injury.
2019 Expert Opin Pharmacother Evaluating crisaborole as a treatment option for atopic dermatitis.
2019 Exp Ther Med Phosphodiesterase 4 inhibitor plus metformin is erior to metformin alone for the treatment of polycystic ovary syndrome: A rat model study.
2019 Skin Therapy Lett Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis
2019 J Dermatol Favorable response to apremilast in a patient with refractory psoriasis verrucosa.
2019 Hautarzt [Gastrointestinal side effects of apremilast : Characterization and management].
2020 J Dermatolog Treat Off-label studies on apremilast in dermatology: a review.
2019 PLoS One Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes.
2019 Jul Acta Derm Venereol Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
2019 Apr Life Sci Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMPCREBTLR4 inflammatory and fibrogenic pathways.
2019 Biochem Pharmacol The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
2019 Comb Chem High Throughput... Comparison of the Full-Length and 152~528 Truncate of Human Cyclic Nucleotide Phosphodiesterase 4B2 for the Characterization of Inhibitors.
2019 Curr Top Med Chem Resveratrol in Various Pockets: A Review.
2019 Ther Adv Musculoskelet Dis IL-12IL-23p40 identified as a downstream target of apremilast in iex vivoi models of arthritis.
2019 Mar Neurosci Res Adolescent psychosocial stress enhances sensitization to cocaine exposure in genetically vulnerable mice.
2019 Apr Eur J Med Chem Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect.
2019 May Free Radic Biol Med Inhibition of PDE4 by FCPR16 induces AMPK-dependent autophagy and confers neuroprotection in SH-SY5Y cells and neurons exposed to MPP+-induced oxidative insult.
2019 Feb J Drugs Dermatol Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study
2019 Biochem Pharmacol FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemiareperfusion injury through activation of the AKTGSK3β β-catenin signaling pathway.
2019 Neurobiol Aging Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study.
2019 Indian Dermatol Online J Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.
2019 Apr Am J Physiol Lung Cell Mo... Extracellular vesicles: another compartment for the second messenger, cyclic adenosine monophosphate.
2019 Hum Exp Toxicol Roflumilast, a phosphodiesterase 4 inhibitor, attenuates cadmium-induced renal toxicity via modulation of NF-κB activation and induction of NQO1 in rats.
2019 Apr Eur J Pharmacol TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model.
2019 Jan BMJ Case Rep Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.